Mortality Reduced by 75%, page-64

Fantastic explanation and certainly a News making headline..
Mortality Reduced by 75% We are talking about the sickest of the sick, the dying people, the urgent and most relevant need in this worldwide pandemic.It is not sensationalism!
"Ventilator-dependentCOVID-19patients with moderate/severe acute respiratory distress syndrome (ARDS)"The otherwise dying!
Mortality Reduced by 75%!!! Yes, "when combined with dexamethasone"
it is the combined effect but if you look at the numbers, I believe the effectiveness of dexamethasone is enhanced by REMESTEMCEL-L
..Hypothesis.......

Corticosteroidsfor COVID-19-Associated ARDS

Clinical Pulmonary Medicine. 2020 Nov; 27(6): 165–167.

Published online 2020Dec 30. doi: 10.1097/CPM.0000000000000381

In June 2020, the RECOVERY trial, a large-scalerandomized control trial preliminary report cemented the role ofcorticosteroids in the care of patients with moderate to severe COVID-19infection. A multicenter, open-label trial from the United Kingdom releaseddata suggesting a 28-day mortality benefit of low-dose dexamethasone, 6 mgdaily, in patients hospitalized with COVID-19 infection.29 The benefit of corticosteroids was greatest in patients who required mechanical ventilation, with an associated 36% relative mortality reduction and 12% absolute mortality reduction. Among those patients requiring supplemental oxygen, the benefit was less pronounced with a 4% absolute mortality reduction. For those individuals without any oxygen requirement, the use of low-dose corticosteroids was not associated with a mortality benefit and suggested a trend toward harm.
..

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC778706..
..
..REMESTEMCEL-L REDUCES MORTALITY IN PATIENTS LESS THAN 65 YEARS OLD WITH
MODERATE/SEVERE COVID-19 ARDS: TOPLINE 60-DAY RESULTS FROM RANDOMIZED
CONTROLLED TRIAL

Remestemcel-L reduced mortality through day 60 by 46% in the prespecified group below age 65, but not in patients 65 or older. Remestemcel-L reduced mortality by 75% and increased days alive off mechanical ventilation in patients under age 65 when combined with dexamethasone, in comparison with controls on dexamethasone.
..
http://investorsmedia.mesoblast.com/static-files/5e07904d-a452-46fb-977f-6b00cd79b992

..
I know the study above is only 28 days.

Nevertheless...
There is a mortality reduction improvement over Remestemcel-L alone of 29% when combined with dexamethasone.
What was the control mortality reduction using dexamethasone on its own? Was the control anywhere near 29%?
I would love to understand this more.

I think we have much more great news to come from this trial by MSB and tremendous support for the collaboration agreement with Novartis.